Roger Song Analyst Performance

Biotech Equity Research at Jefferies Financial Group

Roger Song is a stock analyst at Jefferies Financial Group in the healthcare sector, covering 30 publicly traded companies. Over the past year, Roger Song has issued 28 stock ratings, including buy and hold recommendations. While full access to Roger Song's proprietary MarketBeat Analyst Ranking is reserved for MarketBeat All Access subscribers, the rating is updated daily to reflect the most recent analyst activity. This profile highlights Roger Song's coverage history, rating activity, and performance tendencies - helping individual investors make more informed trading decisions.

Analyst Rankings, Coverage, and Performance Statistics

Average Return
00.00% 12-Month ROI
Success Rate
00.00% Profitable Ratings
Total Ratings
49 Last 5 Years
Buy Recommendations
91.84% 45 Buy Ratings
Companies Covered
30 Unique Companies

Ratings Distribution

RatingPercentageCount
Strong Buy0.0%0 ratings
Buy91.8%45 ratings
Hold8.2%3 ratings
Sell0.0%0 ratings

Out of 49 total stock ratings issued by Roger Song at Jefferies Financial Group, the majority (91.8%) have been Buy recommendations, followed by 8.2% Hold.

Exchange Coverage

ExchangePercentageCount
NASDAQ
96.7% of companies on NASDAQ
29 companies
NYSE
3.3% of companies on NYSE
1 company

Roger Song, an analyst at Jefferies Financial Group, currently covers 30 companies listed on NASDAQ and NYSE, with the majority traded on NASDAQ.

Coverage Focus

Sector IconSectorPercentage
Healthcare
30 companies
100.0%

Roger Song of Jefferies Financial Group specializes in stock coverage within the Healthcare sector.

Coverage Industries

IndustryPercentage
BIOTECHNOLOGY
27 companies
90.0%
PHARMACEUTICALS
3 companies
10.0%

Roger Song's Ratings History at Jefferies Financial Group

Recommendation ROI is the percentage between the price on the Report Date to the price 12 months after the report date.
Available with a MarketBeat All Access Subscription
12-Month ROIUpgrade to All Access to use the All ROI Filter
0 Results
CompanyReport DateActionReport Date Price12-Month
Price Target
Rating12-Month
Price & ROI
Details
Equillium, Inc. stock logo
EQ
Equillium
11/13/2026Set Price Target$1.32$4.00Buy
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
11/6/2026Reiterated Rating$1.21$8.00Buy
AbCellera Biologics Inc. stock logo
ABCL
AbCellera Biologics
10/30/2026Initiated Coverage$12.10$21.00Buy
Disc Medicine, Inc. stock logo
IRON
Disc Medicine
10/21/2026Reiterated Rating$76.00$149.00Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
10/14/2026Reiterated Rating$543.40$728.00Buy
Inovio Pharmaceuticals, Inc. stock logo
INO
Inovio Pharmaceuticals
8/13/2026Upgrade$0.77$3.00Positive
Veradermics, Incorporated stock logo
MANE
Veradermics
7/7/2026Boost Price Target$119.47$182.00Buy
Nurix Therapeutics, Inc. stock logo
NRIX
Nurix Therapeutics
6/8/2026Boost Price Target$15.59$45.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
5/20/2026Initiated Coverage$3.55$11.00Buy
SAB Biotherapeutics, Inc. stock logo
SABS
SAB Biotherapeutics
5/20/2026Initiated Coverage$3.68$11.00Buy
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
5/12/2026Initiated Coverage$22.93$48.00Buy
Kailera Therapeutics, Inc. stock logo
KLRA
Kailera Therapeutics
5/12/2026Initiated Coverage$22.30$48.00Buy
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/28/2026Boost Price Target$53.40$71.00Buy
Replimune Group, Inc. stock logo
REPL
Replimune Group
4/13/2026Downgrade$4.77$2.00Hold
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
4/13/2026Boost Price Target$2.28$10.00Buy
Allogene Therapeutics, Inc. stock logo
ALLO
Allogene Therapeutics
4/10/2026Initiated Coverage$2.67$6.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
3/18/2026Reiterated Rating$98.30$121.00Buy
CytomX Therapeutics, Inc. stock logo
CTMX
CytomX Therapeutics
3/18/2026Boost Price Target$4.73$16.00Buy
Veradermics, Incorporated stock logo
MANE
Veradermics
3/2/2026Initiated Coverage$45.70$75.00Buy
Veradermics, Incorporated stock logo
MANE
Veradermics
3/2/2026Initiated Coverage$46.54$75.00Buy
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
2/17/2026Boost Price Target$295.25$371.00Buy
Protagonist Therapeutics, Inc. stock logo
PTGX
Protagonist Therapeutics
2/2/2026Boost Price Target$83.05$118.00Buy
Corvus Pharmaceuticals, Inc. stock logo
CRVS
Corvus Pharmaceuticals
1/22/2026Boost Price Target$25.92$42.00Buy
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
1/6/2026Reiterated Rating$16.61$48.00Buy
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
12/17/2025Reiterated Rating$49.16Buy
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
11/24/2025Reiterated Rating$54.28$121.00Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
11/19/2025Reiterated Rating$476.59$575.00Buy
Oruka Therapeutics, Inc. stock logo
ORKA
Oruka Therapeutics
11/13/2025Initiated Coverage$28.30$45.00Buy
United Therapeutics Corporation stock logo
UTHR
United Therapeutics
10/29/2025Reiterated Rating$455.32Buy
Zenas BioPharma, Inc. stock logo
ZBIO
Zenas BioPharma
10/27/2025Reiterated Rating$31.98$52.00Buy
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
10/10/2025Initiated Coverage$7.15$16.00Buy
Gyre Therapeutics, Inc. stock logo
GYRE
Gyre Therapeutics
10/10/2025Initiated Coverage$8.01$16.00Buy
Tourmaline Bio, Inc. stock logo
TRML
Tourmaline Bio
9/9/2025Downgrade$47.64$47.50Hold
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
8/28/2025Initiated Coverage$1.86$5.00Buy
Biomea Fusion, Inc. stock logo
BMEA
Biomea Fusion
8/28/2025Initiated Coverage$1.92$5.00Buy
aTyr Pharma, Inc. stock logo
ATYR
aTyr Pharma
8/22/2025Boost Price Target$213.04$680.00Buy
LAVA Therapeutics N.V. stock logo
LVTX
LAVA Therapeutics
8/5/2025Downgrade$1.47$1.50Hold
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
7/29/2025Boost Price Target$30.37$54.00Buy
Replimune Group, Inc. stock logo
REPL
Replimune Group
7/22/2025Lower Price Target$2.92$6.00Buy
CureVac N.V. stock logo
CVAC
CureVac
6/13/2025Reiterated Rating$5.60$5.00Hold
Financial legend: “This is bad, really bad...” (Ad)

Dr. Martin D. Weiss has publicly predicted six major American financial crashes over his 55-year career leading Weiss Ratings, the only conflict-free rating agency in the US. Now he says a $3 trillion problem could trigger a chain reaction of crashes and failures, causing a global freeze in financial markets.tc pixel

See Dr. Weiss's full warning before the next crisis hits.
Kiniksa Pharmaceuticals International, plc stock logo
KNSA
Kiniksa Pharmaceuticals International
4/29/2025Boost Price Target$25.88$45.00Buy
Nektar Therapeutics stock logo
NKTR
Nektar Therapeutics
4/11/2025Upgrade$7.49$30.00Buy
Akebia Therapeutics, Inc. stock logo
AKBA
Akebia Therapeutics
4/1/2025Initiated Coverage$1.92$6.00Buy
Sana Biotechnology, Inc. stock logo
SANA
Sana Biotechnology
3/14/2025Initiated Coverage$2.65$7.00Buy
Krystal Biotech, Inc. stock logo
KRYS
Krystal Biotech
3/5/2025Initiated Coverage$175.22$245.00Buy
WAVE Life Sciences Ltd. stock logo
WVE
WAVE Life Sciences
2/25/2025Initiated Coverage$10.48$26.00Buy